Cardiology Marketing Radiology 
BioTech 365
SEPTEMBER 2, 2020
NASDAQ: MMSI), a leading manufacturer and marketer of proprietary disposable devices used in interventional, diagnostic and therapeutic procedures, particularly in cardiology, radiology, oncology, critical care and endoscopy, … Continue reading → SOUTH JORDAN, Utah, Sept.
The Pharma Data
FEBRUARY 21, 2022
Our leadership in cardiology, radiology and women’s health is recognized worldwide, and we are expanding our presence in oncology, working tirelessly to bring forward new approaches that can change the treatment paradigm for patients,” said Stefan Oelrich, Member of the Board of Management, Bayer AG and President of Bayer’s Pharmaceuticals Division.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
The Pharma Data
JANUARY 19, 2021
“Elcam’s world class production capabilities and experience, will enable mass production and increased market access of Sentinel. Elcam Medical is a world class producer of disposable medical devices and components for the OEM market, and a provider of innovative solutions for specialized flow control needs.
XTalks
JANUARY 19, 2024
Regulatory bodies have demonstrated preparedness for the surge in radiopharmaceuticals as evidenced by inaugural Chemistry, Manufacturing and Controls (CMC) Development and Readiness Pilot (CDRP) programs to expedite commercial manufacturing, US Food and Drug Administration (FDA) approvals and marketing authorizations.
Delveinsight
DECEMBER 29, 2020
Myovant Sciences have decided to put their forces and efforts together to advance the Prostate cancer market as they announced their partnership deal to develop and market relugolix for prostate cancer and women’s health. . Relugolix is a once-daily, oral gonadotropin-release hormone (GnRH) receptor antagonist.
XTalks
SEPTEMBER 11, 2024
It wasn’t until 1999, when the American Heart Association released its Guide to Preventive Cardiology for Women , that the medical field acknowledged that women show different symptoms of the disease than men. This surge reflects a growing recognition of the market potential in addressing women’s health.
The Pharma Data
OCTOBER 14, 2020
“The global heart failure market represents a tremendous opportunity for Sequana Medical and we look forward to providing an update on the interim results from our RED DESERT study later this year.”. market for the alfa pump resulting from NASH-related cirrhosis is forecast to exceed €3 billion annually within the next 10-20 years.
Expert insights. Personalized for you.
40 
Let's personalize your content